Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Revitaderm40 is a topical keratolytic emollient cream developed by Blaine Labs, containing 40% urea as its primary active ingredient. It is designed to treat conditions characterized by thickened or dry skin, such as xerosis, hyperkeratosis, and calluses. Urea acts as a humectant, increasing water retention in the stratum corneum, and as a keratolytic agent, which softens and dissolves the intercellular matrix of the keratinized epithelium. This dual action promotes the exfoliation of dead skin cells and restores the skin's moisture barrier. The formulation often includes supportive botanical ingredients like aloe vera, tea tree oil, and chamomile to soothe the skin. It is particularly marketed for podiatric use, including intensive diabetic foot care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Revitaderm40.